This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Duthie RB, Dodd CAF. Reconstructive surgery and joint replacement. In: The management of musculoskeletal problems in the haemophilias. Duthie RBD, Rizza CR, Giangrande PLF, Dodd CAF. Oxford University Press, 1994 (page 193)
Rodriguez-Merchan EC, Wiedel JD, Wallny T, Caviglia H, Hvid I, Berntorp E, Rivard GE, Goddard NJ, Querol F. Elective orthopedic surgery for hemophilia patients with inhibitors: new opportunities. Seminars in Hematology 41: 109–116 (2004)
Negrier C, Goudemand J, Sultan Y Bertrand M, Rothschild C, Lauroua P and the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and IX inhibitors. Thromb Haemost 1997; 77: 1113–1139
Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year safety compilation of thrombotic adverse events. Haemophilia 2002; 8: 83–90
Franchini M, Tagliaferri A, Rossetti G, Pattacini C, Pozzoli D, Lorenz C, Gandini G. Absence of thromboembolic complications in patients with hereditary bleeding disorders under-going major orthopaedic surgery without antithrombotic prophylaxis. Thromb Haemost 2004; 91: 1053–1055
Rodriguez-Merchan EC, Wiedel JD, Wallny T, Hvid I, Berntorp E, Rivard G-E, Goddard NJ, Querol F, Caviglia H. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625–631
Barrowcliffe TW. Monitoring haemophilia severity and treatment-new or old laboratory tests? 2004 Haemophilia (in press)
Varadi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP, Turecek PL. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374–2380
Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantification of activated FVII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734–44
Cid AR, Lorenzo JI, Haya S, Montoro JM, Casana P, Aznar JA. A comparison of FVII:C and FVIIa assays for monitoring of recombinant factor FVIIa treatment. Haemophilia 2001; 7: 39–41
Villar A, Aronis S, Morfini M, Santagostino E, Aurswald G, Thomsen HF, Erhardtsen, Giangrande PLF. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 1–8
Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. British Journal of Haematology 2003; 120: 808–813
Lacey L. Economic impact of treating inhibitor patients. Pathophysiology of Haemostasis and Thrombosis 2002; 32 (Suppl. 1): 29–32
Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358–63
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Verlag Berlin Heidelberg
About this paper
Cite this paper
Giangrande, P.L.F. (2006). Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors. In: Scharrer, I., Schramm, W. (eds) 35th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28546-6_9
Download citation
DOI: https://doi.org/10.1007/3-540-28546-6_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28543-4
Online ISBN: 978-3-540-28546-5
eBook Packages: MedicineMedicine (R0)